In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Hexal: Generic Consolidation, and More

Executive Summary

Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.

You may also be interested in...



Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)

Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.

Not-For-Profit Makes Business Sense, Too

Not-for-profit drug development and other charitable initiatives haven't had a hugely prominent role at Big Pharma in the past. But nowadays most Big Pharma can point to some sort of benevolent effort, and a few companies view such initiatives as more than just the right thing to do. They claim that not-for-profit R&D makes good business sense, too.

Not-For-Profit Makes Business Sense, Too

Not-for-profit drug development and other charitable initiatives haven't had a hugely prominent role at Big Pharma in the past. But nowadays most Big Pharma can point to some sort of benevolent effort, and a few companies view such initiatives as more than just the right thing to do. They claim that not-for-profit R&D makes good business sense, too.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel